NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 159.74 billion. The enterprise value is 154.90 billion.
Important Dates
The last earnings date was Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Nov 19, 2026 |
Share Statistics
| Current Share Class | 196.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 26.77% |
| Owned by Institutions (%) | 11.51% |
| Float | 100.88M |
Valuation Ratios
The trailing PE ratio is 17.66 and the forward PE ratio is 19.20.
| PE Ratio | 17.66 |
| Forward PE | 19.20 |
| PS Ratio | 5.17 |
| PB Ratio | 1.64 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | 68.82 |
| P/OCF Ratio | 21.51 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 16.94, with an EV/FCF ratio of 66.74.
| EV / Earnings | 18.70 |
| EV / Sales | 5.01 |
| EV / EBITDA | 16.94 |
| EV / EBIT | 21.32 |
| EV / FCF | 66.74 |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.17 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 4.45 |
| Interest Coverage | 14.49 |
Financial Efficiency
Return on equity (ROE) is 9.01% and return on invested capital (ROIC) is 6.15%.
| Return on Equity (ROE) | 9.01% |
| Return on Assets (ROA) | 7.45% |
| Return on Invested Capital (ROIC) | 6.15% |
| Return on Capital Employed (ROCE) | 5.75% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 6.98M |
| Profits Per Employee | 1.87M |
| Employee Count | 4,433 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 0.73 |
Taxes
In the past 12 months, NATCO Pharma has paid 647.00 million in taxes.
| Income Tax | 647.00M |
| Effective Tax Rate | 7.24% |
Stock Price Statistics
The stock price has decreased by -1.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -1.58% |
| 50-Day Moving Average | 808.10 |
| 200-Day Moving Average | 926.16 |
| Relative Strength Index (RSI) | 55.85 |
| Average Volume (20 Days) | 82,299 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 30.92 billion and earned 8.29 billion in profits. Earnings per share was 46.26.
| Revenue | 30.92B |
| Gross Profit | 24.30B |
| Operating Income | 5.66B |
| Pretax Income | 8.94B |
| Net Income | 8.29B |
| EBITDA | 7.51B |
| EBIT | 5.66B |
| Earnings Per Share (EPS) | 46.26 |
Full Income Statement Balance Sheet
The company has 15.17 billion in cash and 10.33 billion in debt, with a net cash position of 4.84 billion.
| Cash & Cash Equivalents | 15.17B |
| Total Debt | 10.33B |
| Net Cash | 4.84B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 97.65B |
| Book Value Per Share | 545.11 |
| Working Capital | 22.85B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 7.43 billion and capital expenditures -5.11 billion, giving a free cash flow of 2.32 billion.
| Operating Cash Flow | 7.43B |
| Capital Expenditures | -5.11B |
| Depreciation & Amortization | 1.84B |
| Net Borrowing | 7.64B |
| Free Cash Flow | 2.32B |
| FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross margin is 78.56%, with operating and profit margins of 18.32% and 26.79%.
| Gross Margin | 78.56% |
| Operating Margin | 18.32% |
| Pretax Margin | 28.91% |
| Profit Margin | 26.79% |
| EBITDA Margin | 24.27% |
| EBIT Margin | 18.32% |
| FCF Margin | 7.51% |
Dividends & Yields
This stock pays an annual dividend of 4.25, which amounts to a dividend yield of 0.52%.
| Dividend Per Share | 4.25 |
| Dividend Yield | 0.52% |
| Dividend Growth (YoY) | 21.43% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.79% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.52% |
| Earnings Yield | 5.66% |
| FCF Yield | 1.45% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for NATCO Pharma is 1,002.11, which is 22.66% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,002.11 |
| Price Target Difference | 22.66% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 2.09% |
| EPS Growth Forecast (3Y) | -10.62% |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |